Biotechs Pressured Following Clinton Tweet (IBB)

Biotech stocks are getting hit on Monday following a post to Twitter by presidential candidate Hillary Clinton.

Clinton noted a New York times piece, which highlights a price increase in Daraprim from $13.50 up to $750 after Turing Pharmaceuticals acquired rights to the drug.

iShares Nasdaq Biotechnology (NYSE: IBB) is down 4.5 percent, Biogen (NASDAQ: BIIB) is down 5.2 percent, Allergan (NYSE: AGN) is down 2.9 percent, Gilead Sciences (NASDAQ: GILD) is down 2.6 percent, Amgen (NASDAQ: AMGN) is down 2.2 percent, Shire plc (NASDAQ: SHPG) is down 1 percent, among others.

The tweet is below:

Price gouging like this in the specialty drug market is outrageous. Tomorrow I'll lay out a plan to take it on. -H https://t.co/9Z0Aw7aI6h

— Hillary Clinton (@HillaryClinton) September 21, 2015

You May Also Be Interested In

• Apple (AAPL) announces 'Let Loose,' a special online event to be held in May
• Nanometrics (NANO) Issues Business Update, Reports FY23 Results
• Rimini Street (RMNI) Appoints Steve Hershkowitz as Chief Revenue Officer